Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study.

Vandenberghe P, Wlodarska I, Tousseyn T, Dehaspe L, Dierickx D, Verheecke M, Uyttebroeck A, Bechter O, Delforge M, Vandecaveye V, Brison N, Verhoef GE, Legius E, Amant F, Vermeesch JR.

Lancet Haematol. 2015 Feb;2(2):e55-65. doi: 10.1016/S2352-3026(14)00039-8. Epub 2015 Jan 20.

PMID:
26687610
2.

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).

Thielen N, van der Holt B, Cornelissen JJ, Verhoef GE, Gussinklo T, Biemond BJ, Daenen SM, Deenik W, van Marwijk Kooy R, Petersen E, Smit WM, Valk PJ, Ossenkoppele GJ, Janssen JJ.

Eur J Cancer. 2013 Oct;49(15):3242-6. doi: 10.1016/j.ejca.2013.06.018. Epub 2013 Jul 19.

3.

Physical activity and risk of lymphoma: a meta-analysis.

Vermaete NV, Wolter P, Verhoef GE, Kollen BJ, Kwakkel G, Schepers L, Gosselink R.

Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1173-84. doi: 10.1158/1055-9965.EPI-13-0182. Epub 2013 May 15. Review.

4.

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.

Thielen N, van der Holt B, Verhoef GE, Ammerlaan RA, Sonneveld P, Janssen JJ, Deenik W, Falkenburg JH, Kersten MJ, Sinnige HA, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IW, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.

Ann Hematol. 2013 Aug;92(8):1049-56. doi: 10.1007/s00277-013-1730-4. Epub 2013 Apr 10.

PMID:
23572137
5.

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).

Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, Ferrant A, Graux C, de Greef GE, Halkes CJ, Hoogendoorn M, Hollestein RM, Jongen-Lavrencic M, Levin MD, van de Loosdrecht AA, van Marwijk Kooij M, van Norden Y, Pabst T, Schouten HC, Vellenga E, Verhoef GE, de Weerdt O, Wijermans P, Passweg JR, Löwenberg B.

Blood. 2012 Dec 6;120(24):4706-11. doi: 10.1182/blood-2012-04-420596. Epub 2012 Oct 9.

PMID:
23047822
6.

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.

Deenik W, Janssen JJ, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Daenen SM, Verdonck LF, Ferrant A, Schattenberg AV, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Beverloo HB, Löwenberg B, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.

Haematologica. 2010 Jun;95(6):914-21. doi: 10.3324/haematol.2009.016766. Epub 2009 Dec 16.

7.

FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.

Karam M, Ata A, Irish K, Feustel PJ, Mottaghy FM, Stroobants SG, Verhoef GE, Chundru S, Douglas-Nikitin V, Oliver Wong CY, Brepoels LM.

Nucl Med Commun. 2009 Oct;30(10):770-8. doi: 10.1097/MNM.0b013e32832e0c13.

PMID:
19657307
8.

Acquired mutations in TET2 are common in myelodysplastic syndromes.

Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH.

Nat Genet. 2009 Jul;41(7):838-42. doi: 10.1038/ng.391. Epub 2009 May 31.

PMID:
19483684
9.

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.

Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachée P, Verdonck LF, Löwenberg B, Dekker AW; Dutch-Belgian HOVON Cooperative Group.

Blood. 2009 Feb 5;113(6):1375-82. doi: 10.1182/blood-2008-07-168625. Epub 2008 Nov 6.

PMID:
18988865
10.

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.

Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJ, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Westveer PH, Beverloo HB, Valk P, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ.

Blood. 2008 Mar 1;111(5):2581-8. doi: 10.1182/blood-2007-08-107482. Epub 2008 Jan 2.

PMID:
18172005
11.

CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.

van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, Vellenga E, Ossenkoppele GJ, Löwenberg B, Sonneveld P.

Ann Hematol. 2007 May;86(5):329-37. Epub 2007 Mar 6.

12.

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.

Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, Westveer PH, Poddighe PJ, Verhoef GE, Sonneveld P; Dutch-Belgian Haemato-Oncology Cooperative Study Group (HOVON); Dutch Working Party on Cancer Genetics and Cytogenetics (NWCGC).

Br J Haematol. 2007 Feb;136(4):615-23.

PMID:
17223915
13.

Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Verdonck LF, Notenboom A, de Jong DD, MacKenzie MA, Verhoef GE, Kramer MH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, van Imhoff GW.

Blood. 2007 Apr 1;109(7):2759-66.

PMID:
17132720
14.

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study.

Deenik W, van der Holt B, Verhoef GE, Schattenberg AV, Verdonck LF, Daenen SM, Zachée P, Westveer PH, Smit WM, Wittebol S, Schouten HC, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ.

Ann Hematol. 2007 Feb;86(2):117-25. Epub 2006 Oct 10.

PMID:
17031690
15.

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.

van der Holt B, Löwenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, Ossenkoppele GJ, Verhoef GE, Ferrant A, Crump M, Selleslag D, Theobald M, Fey MF, Vellenga E, Dugan M, Sonneveld P.

Blood. 2005 Oct 15;106(8):2646-54. Epub 2005 Jun 30.

PMID:
15994288
16.

Prognostic index for adult patients with acute myeloid leukemia in first relapse.

Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, Vellenga E, De Greef GE, Jacky E, Van der Lelie J, Boogaerts MA, Löwenberg B.

J Clin Oncol. 2005 Mar 20;23(9):1969-78. Epub 2005 Jan 4.

PMID:
15632409
17.
18.

Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.

Daenen S, van der Holt B, Verhoef GE, Löwenberg B, Wijermans PW, Huijgens PC, van Marwijk Kooy R, Schouten HC, Kramer MH, Ferrant A, van den Berg E, Steijaert MM, Verdonck LF, Sonneveld P.

Leuk Res. 2004 Oct;28(10):1057-67.

PMID:
15289018
19.

The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.

Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, Westveer PH, Peters GJ, Noordhuis P, Muus P, Selleslag D, van der Holt B, Delforge M, Löwenberg B, Verhoef GE; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Blood. 2004 Apr 15;103(8):2908-13. Epub 2003 Dec 4. Erratum in: Blood. 2004 Jul 1;104(1):42.

PMID:
15070662
20.

Case of megaloblastic anemia caused by intestinal taeniasis.

Vuylsteke P, Bertrand C, Verhoef GE, Vandenberghe P.

Ann Hematol. 2004 Jul;83(7):487-8. Epub 2004 Jan 17.

PMID:
14730392
21.

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.

Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GE, Steijaert MM, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P.

J Clin Oncol. 2003 Aug 15;21(16):3041-50.

PMID:
12915593
22.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Blood. 2003 Mar 15;101(6):2144-51. Epub 2002 Nov 27.

PMID:
12456509
23.

[A man with plasma cell dyscrasia and polyneuropathy due to POEMS syndrome].

Driessens SK, Wildiers H, Verhoef GE, Vanstraelen D, Robberecht W, Vandenberghe P.

Ned Tijdschr Geneeskd. 2002 Feb 16;146(7):321-5. Dutch.

PMID:
11876037
24.

Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia.

Devriendt K, Kim AS, Mathijs G, Frints SG, Schwartz M, Van Den Oord JJ, Verhoef GE, Boogaerts MA, Fryns JP, You D, Rosen MK, Vandenberghe P.

Nat Genet. 2001 Mar;27(3):313-7.

PMID:
11242115
25.

P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.

van der Kolk DM, de Vries EG, van Putten WJ, Verdonck LF, Ossenkoppele GJ, Verhoef GE, Vellenga E.

Clin Cancer Res. 2000 Aug;6(8):3205-14.

26.

Disseminated infection by Scedosporium prolificans: an emerging fatality among haematology patients. Case report and review.

Maertens J, Lagrou K, Deweerdt H, Surmont I, Verhoef GE, Verhaegen J, Boogaerts MA.

Ann Hematol. 2000 Jun;79(6):340-4.

PMID:
10901616
27.

Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests.

Janssen JJ, van Rijn RS, van der Holt B, Schuurhuis GJ, Vellenga E, Verhoef GE, Ossenkoppele GJ, van den Berg E, Hagemeijer A, Släter R, Nieuwint AW, Cornelissen JJ.

Bone Marrow Transplant. 2000 Jun;25(11):1147-55.

28.

Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis.

Maertens J, Demuynck H, Verbeken EK, Zachée P, Verhoef GE, Vandenberghe P, Boogaerts MA.

Bone Marrow Transplant. 1999 Aug;24(3):307-12.

29.

A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group.

Ossenkoppele GJ, van der Holt B, Verhoef GE, Daenen SM, Verdonck LF, Sonneveld P, Wijermans PW, van der Lelie J, van Putten WL, Löwenberg B.

Leukemia. 1999 Aug;13(8):1207-13.

30.

Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?

Vellenga E, van Putten WL, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Jonkhoff AR, Huijgens PC, Verdonck LF, van der Lelie J, Schouten HC, Gmür J, Wijermans P, Gratwohl A, Hess U, Fey MF, Löwenberg B.

Bone Marrow Transplant. 1999 Jun;23(12):1279-82.

31.

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.

Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM.

Br J Haematol. 1999 Apr;105(1):127-30.

PMID:
10233375
32.

Lymphocyte profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: flow-cytometric characterization and analysis in a two-dimensional correlation biplot.

Van den Hove LE, Meeus P, Derom A, Demuynck H, Verhoef GE, Vandenberghe P, Boogaerts MA.

Ann Hematol. 1998 Jun;76(6):249-56.

PMID:
9692812
33.

Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment.

Van den Hove LE, Vandenberghe P, Van Gool SW, Ceuppens JL, Demuynck H, Verhoef GE, Boogaerts MA.

Leuk Res. 1998 Feb;22(2):175-84.

PMID:
9593474
34.

Autologous peripheral blood progenitor cell transplantation in patients with high-risk myelodysplastic syndromes.

Verhoef GE, Demuynck H, Delforge M, Vandenberghe P, Maertens J, Zachée P, Boogaerts M.

Pathol Biol (Paris). 1997 Oct;45(8):651-5.

PMID:
9569931
35.

Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.

Löwenberg B, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Vellenga E, Ossenkoppele GJ, Huijgens PC, Verdonck LF, van der Lelie J, Wielenga JJ, Schouten HC, Gmür J, Gratwohl A, Hess U, Fey MF, van Putten WL.

J Clin Oncol. 1997 Dec;15(12):3496-506.

PMID:
9396403
36.
37.
38.

Multivariate reconstruction of lymphocyte profiles in a two-dimensional graphical model as a tool for the investigation of lymphocyte subset distribution in health and disease.

Van den Hove LE, Symons F, Vandenberghe P, Verhoef GE, Demuynck H, Van Gool SW, Ceuppens JL, Boogaerts MA.

Cytometry. 1997 Jul 1;28(3):220-7.

39.

Successful control of refractory and life-threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with the primary antiphospholipid syndrome.

Vandenberghe P, Zachee P, Verstraete S, Demuynck H, Boogaerts MA, Verhoef GE.

Ann Hematol. 1996 Nov;73(5):253-6.

PMID:
8959944
40.

Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.

Demuynck H, Verhoef GE, Zachee P, Emonds MP, van der Schueren E, van den Berghe H, Vandenberghe P, Casteels-Van Daele M, Boogaerts MA.

Bone Marrow Transplant. 1996 May;17(5):745-51.

PMID:
8733692
41.

Treatment and prognostic factors in myelodysplastic syndromes.

Boogaerts MA, Verhoef GE, Demuynck H.

Baillieres Clin Haematol. 1996 Mar;9(1):161-83. Review.

PMID:
8730556
42.

Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes.

Demuynck H, Delforge M, Verhoef GE, Zachee P, Vandenberghe P, Van den Berghe H, Boogaerts MA.

Br J Haematol. 1996 Feb;92(2):351-9.

PMID:
8602999
43.

Cytogenetics and its prognostic value in myelodysplastic syndromes.

Verhoef GE, Boogaerts MA.

Acta Haematol. 1996;95(2):95-101. Review.

PMID:
8638447
44.

Therapy-related acute myeloid leukemia with t(8;16)(p11;p13) following anthracycline-based therapy for nonmetastatic osteosarcoma.

Demuynck H, Verhoef GE, Zachée P, Vandenberghe P, Van Orshoven A, Paridaens R, Samson I, Boogaerts MA.

Cancer Genet Cytogenet. 1995 Jul 15;82(2):103-5.

PMID:
7664238
45.

FAB classification of myelodysplastic syndromes: merits and controversies.

Verhoef GE, Pittaluga S, De Wolf-Peeters C, Boogaerts MA.

Ann Hematol. 1995 Jul;71(1):3-11. Review.

PMID:
7632816
46.

An update on peripheral blood progenitor cell transplantation.

Demuynck H, Delforge M, Zachée P, Verhoef GE, Vandenberghe P, Boogaerts MA.

Ann Hematol. 1995 Jul;71(1):29-33. Review.

PMID:
7632815
47.

Risks of rhG-CSF treatment in drug-induced agranulocytosis.

Demuynck H, Zachée P, Verhoef GE, Schetz M, Van den Berghe G, Lauwers P, Boogaerts MA.

Ann Hematol. 1995 Mar;70(3):143-7.

PMID:
7536476
48.

Platelet ultrastructural and functional studies in myelodysplasia.

Blockmans D, Heynen MJ, Verhoef GE, Vermylen J.

Haematologia (Budap). 1995;26(3):159-72.

PMID:
7797146
49.

Hypercalcemia, monoclonal protein, and osteolytic bone lesions in chronic lymphocytic leukemia.

Van de Casteele M, Verhoef GE, Demuynck H, Zacheé P, Boogaerts MA.

Ann Hematol. 1994 Aug;69(2):79-80.

PMID:
8080883
50.

Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two?

Verhoef GE, Demuynck H, Zachee P, Boogaerts MA.

Leukemia. 1994 Apr;8(4):714-5. Review. No abstract available.

PMID:
8152271

Supplemental Content

Loading ...
Support Center